Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY2300559 in Patients With Migraine
NCT01184508Phase 2Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2011
- Primary completion
- Apr 2012
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in migraine comparing LY2300559 with Placebo (2 arms). Primary endpoint: Change From Baseline to 12 Week Endpoint in the Number of Migraine Attacks. Started Jan 2011; status: terminated.
02
Drugs
LY-2300559
03
Conditions
migraine
Beyond the preview
Go deeper on NCT01184508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01184508.